MannKind Corporation (MNKD) COO Hakan Edstrom says his company is “looking closely” at expansion opportunities in the pain management market.
“If you get the medication into the bloodstream very quickly, you also have a relief of the pain much, much quicker. There are also nonopioid opportunities, where you may even be able to treat patients for their pain without having the risk of them getting into situations where they are dependent on the drug itself because of the side effects,” Edstrom says. “That’s one area that we are looking into right now, and there are some others that I, unfortunately for proprietary reasons, cannot necessarily speak on at this point in time.”
FOR MORE INFORMATION ON THIS INTERVIEW CLICK HERE.
Edstrom says MannKind is still in the preclinical phase of its pain management research. He says the company has conducted feasibility studies, but not yet moved on to subsequent phases of research.
“We have had to manage our resources because AFREZZA has been such a major undertaking for the company,” Edstrom says. “We’ve had to be a little bit more conservative in the investment in other areas until we feel that we have a successful product on the market and a partnership, which is what we’re looking to with AFREZZA.”
Skilled Healthcare Group, Inc. (SKH) Restructures Balance Sheet and Considers Options with 77% Facility Ownership
July 25, 2013
Walgreens Boots Alliance Inc (WAG) Entering Telehealth Market
May 15, 2015
EU Equity Markets are Entering a Volatile Phase with Italy as a Cause
July 10, 2019
AcelRx Pharmaceuticals Inc (ACRX) Prepares to Launch Lead Product Zalviso to Manage Postoperative Pain Nonintravenously
August 22, 2013
Petra Foods Limited (SGX:P34) Holds 50% Market Share in Growing Indonesian Chocolate Market
June 25, 2013
